Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.76 |
| ▸ | EGFR | P00533 | 7/20 | 0.76 |
| ▸ | IGF1R | P08069 | 6/20 | 0.71 |
| ▸ | INSR | P06213 | 5/20 | 0.71 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.64 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150200 | 0.97 | ALK (0.74) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL21164626 | 0.95 | ALK (0.72) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL16780721 | 0.93 | ALK (0.74) | ALKEGFRIGF1RINSREML4 | |
| SCHEMBL16780916 | 0.91 | ALK (0.78) | ALKEGFRIGF1RINSREML4 | |
| SCHEMBL15600820 | 0.91 | ALK (0.74) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL31196996 | 0.91 | ALK (0.78) | ALKEGFRIGF1RINSREML4 | |
| SCHEMBL19027971 | 0.90 | ALK (0.66) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL14150164 | 0.90 | EGFR (0.71) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL16780999 | 0.89 | ALK (0.72) | ALKEGFRIGF1RINSRMAP4K1 | |
| SCHEMBL15600815 | 0.89 | ALK (0.72) | ALKEGFRIGF1RINSREML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | claimed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | claimed |
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2018-12-27 | — | — | US | disclosed |
| EP-3392245-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-10-24 | — | — | EP | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | ALK 161/4885EGFR 3/4885IGF1R 675/4885 |
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | ALK, EGFR, NPM1 | ALK 1/4885EGFR 2/4885IGF1R 228/4885 |
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | ALK 1/4885EGFR 2/4885IGF1R 212/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | ALK 293/4885EGFR 1/4885IGF1R 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.